AGP Executive Report
Last update: 6 hours agoSleep Research: A Cochrane review of nine trials found little to no meaningful sleep benefit from medical cannabis compared with placebo. The studies were small and short, so researchers say the evidence remains too weak for firm conclusions. Product Safety: Colorado officials say dozens of people have reported adverse health effects after a major THC vape recall. Inspectors found banned solvents, pesticides and additives in products sold at more than 700 dispensaries. CBD and Hemp Market: Looming federal hemp restrictions could force some CBD and THC products off store shelves, putting pressure on online sellers and small brands. Cannabis and Health: A federally funded study reported that medical cannabis improved cancer-related symptoms and reduced opioid use. Separately, mouse research suggests cannabinoids can amplify fear responses under stress, offering a possible clue to cannabis-related anxiety—but not proof of the same effect in people.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
